Abeona Therapeutics (ABEO) Cash from Investing Activities (2011 - 2026)

Abeona Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 17.8% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $105.8 million (up 488.75% YoY), while the FY2025 annual figure was $105.0 million, up 367.66% from the prior year.
• Cash from Investing Activities was $5.0 million for Q1 2026 at Abeona Therapeutics, down from $9.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $155.9 million in Q2 2025 to a low of -$64.6 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged $2.8 million across 5 years, with a median of $1.6 million in 2022.
• Biggest YoY gain for Cash from Investing Activities was 472.75% in 2023; the steepest drop was 1236.63% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$25.3 million in 2022, then surged by 145.59% to $11.5 million in 2023, then jumped by 63.73% to $18.9 million in 2024, then slumped by 49.39% to $9.6 million in 2025, then plunged by 48.05% to $5.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $5.0 million (Q1 2026), $9.6 million (Q4 2025), and -$64.6 million (Q3 2025), per Business Quant data.